Clover Health Investments Corp [NASDAQ: CLOV] price surged by 3.10 percent to reach at $0.13.
The one-year CLOV stock forecast points to a potential downside of -41.04. The average equity rating for CLOV stock is currently 2.33, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Guru’s Opinion on Clover Health Investments Corp [CLOV]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLOV shares is $3.07 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLOV stock is a recommendation set at 2.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Clover Health Investments Corp shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on October 07, 2024. While these analysts kept the previous recommendation, Cowen dropped their target price from $7 to $3. The new note on the price target was released on February 02, 2022, representing the official price target for Clover Health Investments Corp stock. Previously, the target price had yet another raise to $6, while Canaccord Genuity analysts kept a Buy rating on CLOV stock.
The Average True Range (ATR) for Clover Health Investments Corp is set at 0.25, with the Price to Sales ratio for CLOV stock in the period of the last 12 months amounting to 1.30. The Price to Book ratio for the last quarter was 6.42.
CLOV Stock Performance Analysis:
Clover Health Investments Corp [CLOV] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.71. With this latest performance, CLOV shares gained by 7.18% in over the last four-week period, additionally plugging by 501.31% over the last 6 months – not to mention a rise of 328.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLOV stock in for the last two-week period is set at 68.97, with the RSI for the last a single of trading hit 72.90, and the three-weeks RSI is set at 67.18 for Clover Health Investments Corp [CLOV]. The present Moving Average for the last 50 days of trading for this stock 3.40, while it was recorded at 4.15 for the last single week of trading, and 1.72 for the last 200 days.
Insight into Clover Health Investments Corp Fundamentals:
Clover Health Investments Corp’s liquidity data is similarly interesting compelling, with a Current Ratio set at 1.69.
CLOV Stock EPS
With the latest financial reports released by the company, Clover Health Investments Corp posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.11/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.02. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLOV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clover Health Investments Corp go to 19.10%.
Clover Health Investments Corp [CLOV] Institutonal Ownership Details
There are presently around $18.35%, or 19.42%% of CLOV stock, in the hands of institutional investors. The top three institutional holders of CLOV stocks are: VANGUARD GROUP INC with ownership of 17.35 million shares, which is approximately 3.5662%. RENAISSANCE TECHNOLOGIES LLC, holding 11.27 million shares of the stock with an approximate value of $$13.86 million in CLOV stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $$11.73 million in CLOV stock with ownership which is approximately 1.9613%.
